ClinicalTrials.gg
CompletedNCT05489757SPY Q-ICG PASUpdated Oct 27, 2026

Quantitative Fluorescence Angiography With ICG for Perfusion Assessment During Surgery

An interventional study of SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software in Esophageal Cancer and Colorectal (Colon or Rectal) Cancer, sponsored by IRCCS San Raffaele. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2022, registered Jun 2022).
Updated Oct 27, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Esophageal Neoplasms with a site in Italy — 17 open to participants now, 23 under way, 4 of them phase 3. Esophageal Neoplasms · Italy.

Enrollment
21st of 38
196 · median 205
Started
2022
with 4 others
No phase
11 of 50
2 open now
Registered
33rd of 50
by date
Lead sponsor
4 of 50
IRCCS San Raffaele

Among the 50 studies in Esophageal Neoplasms with a site in Italy, this one is the 21st largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2022, is one of 11 with no phase, and was the 33rd registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 50 studies in Esophageal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Esophageal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The accurate assessment of intraoperative tissue perfusion is essential in any branch of surgery. Anastomotic leakage (AL) is one of the most feared complications following gastrointestinal surgery, with potentially threatening consequences resulting in worsened short- and long-term outcomes. Consistently, a recent meta-analysis showed a correlation between AL and shorter disease-free survival in colorectal surgery. Despite its multifactorial origin, AL is highly related to inadequate visceral perfusion. Traditionally, perfusion assessment and subsequent anastomotic viability have been evaluated by surgeons using intraoperative indicators, such as color, pulsation of vessels, presence of peristalsis and bleeding from the resection lines. However, these clinical parameters are not able to reliably assess the real visceral perfusion and their evaluation is limited in minimally invasive surgery. Hence, the growing interest for innovative techniques able to properly assess tissue perfusion. Among these, the fluorescence angiography (FA) with indocyanine green (ICG) has become increasingly popular during the last decade, although its approval for biomedical purposes by the Food and Drug Administration (FDA) dates back to 1956. ICG is an amphiphilic, non-toxic, tricarbocyanine iodide dye that can be safely injected intravenously and is exclusively eliminated by the liver, without any absorption. Thanks to its fluorescent properties, it allows the real-time visualization of tissue vascularization. FA with ICG has shown promising results for the evaluation of perfusion in numerous surgical procedures, thus leading to modifications of the surgical strategy and consequently to a decrease in the rates of AL. On the other hand, ICG interpretation is subjective, based on the evaluation of fluorescence performed by the operating surgeon. These results lack into a high inter-observer variability and affect the possibility to obtain objective, reproducible and reliable tissue perfusion assessments.

Quantitative fluorescence angiography with ICG (Q-ICG) could overcome these limitations. In Q-ICG the fluorescence signal is elaborated by a new computer quantification algorithm and translated into a fluorescence-time curve (FTC), from which several Q-ICG parameters and values can be extracted. Given the power of ICG in reflecting the perfusion of examined tissues, a new quantification algorithm has the potential to turn the subjective parameters derived from surgeon's perspective into objective numeric values.

The primary aim of this study is to evaluate which Q-ICG values provided by a new quantification algorithm correspond to subjective perfusion parameters usually evaluated by the surgeon in patients undergoing left colon, rectal or esophagogastric resections.

The secondary aim is to evaluate possible correlations between Q-ICG values provided by the quantification algorithm and perioperative outcomes.

Read the detailed description

The study is designed as a prospective, observational, monocentric, cohort study on algorithm. At our Institution ICG is already used routinely to assess visceral perfusion during gastrointestinal operations. We plan to enroll 70 patients for esophagogastric resections and 140 patients for colorectal resections. Firstly, the adequacy of colon or gastric perfusion will be assessed by the surgical team in the traditional way. Color, pulsatile flow of vessels (right gastroepiploic arcade for the gastric conduit, marginal artery for the colon), presence of peristalsis and bleeding from the colic resection lines will be considered as parameters of perfusion. Then, ICG will be injected, Q-ICG analysis will be performed in all the patients by using a new quantification algorithm and data will be recorded and reported in a specific Database. The surgical strategy will not be modified based on Q-ICG results.

03

Conditions studied

  • Esophageal Cancer
  • Colorectal (Colon or Rectal) Cancer

Keywords

  • ICG quantification
  • Esophagectomy
  • Colorectal resection
  • Perfusion assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is willing and able to give for participation in the trial
  • Male and Female, Age > 18 years
  • Patients undergoing left colon, rectal or esophagogastric resections
  • Patients with malignant or benign disease
  • Minimally invasive or open approach surgery

Exclusion criteria

Exclusion Criteria:

  • Absence of esophagogastric or colorectal reconstruction (e.g. Miles procedure)
  • Limited sigmoid resection without ligation of the inferior mesenteric artery
  • Known allergies, or intolerance to indocyanine green (ICG) or iodine contrast agents,
  • Patients with hyperthyroidism or benign thyroid tumor
  • Acute or chronic kidney failure (stage ≥ 3)
  • Pregnant or lactating women, or with a positive pregnancy test performed before surgery
  • Any clinical condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Perfusion assessment with SPY Q-ICG system

    Device: SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software Description: Perfusion assessment with SPY Q-ICG system

    Device: SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software

Interventions

  • DeviceSPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software

    Perfusion assessment with SPY Q-ICG system

06

What researchers measure

Primary outcomes

  1. Maximum intensity of ICG fluorescence

    % (absolute value)

    Time frame: One timepoint: at day 0, after the externalization of colon/stomach, before packing the colorectal/esophagogastric anastomosis.

  2. Time to first ICG fluorescence signal

    seconds

    Time frame: One timepoint: at day 0, after the externalization of colon/stomach, before packing the colorectal/esophagogastric anastomosis.

  3. Time-to-peak

    seconds

    Time frame: One timepoint: at day 0, after the externalization of colon/stomach, before packing the colorectal/esophagogastric anastomosis.

Secondary outcomes

  1. Correlation with postoperative outcomes

    The rate of anastomotic leakage in patients who underwent colorectal or esophagogastric resections

    Time frame: From day 0 to day 30 after discharge

07

Study locations

1 site
  • Riccardo Rosati
    Milan, Milan 20132, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in May 2026, 51 months.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's 51 months is above that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Nov 2024 → May 2026 and completion Dec 2024 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Aug 5, 2022
StartActual
Feb 16, 2022
Primary completionActual
May 19, 2026was Nov 2024
CompletionActual
May 19, 2026was Dec 2024
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Sites
1 site added, 1 site removed
Show site
  • Riccardo Rosati · Milan, Italy
Show 1 removed
  • Lorenzo Cinelli · Milan, Italy
Oct 27, 2026
Primary completion
Nov 30, 2024→May 19, 2026 (actual)
Oct 27, 2026
Study completion
Dec 31, 2024→May 19, 2026 (actual)
Oct 27, 2026
Enrollment
239 (estimated)→196 (actual)
Oct 27, 2026
Interventions
Arms or interventions changed
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Riccardo Rosati · Milan, Italy
    Show 1 removed
    • Lorenzo Cinelli · Milan, Italy
    Primary completion Nov 30, 2024→May 19, 2026 (now actual)
    Study completion Dec 31, 2024→May 19, 2026 (now actual)
    Enrollment 239 (estimated)→196 (actual)
    Interventions Arms or interventions changed
    + 4 other changes: verification date, responsible party, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05489757
Lead sponsor
IRCCS San Raffaele
Responsible party
Riccardo Salvatore Rosati (Professor of Surgery - Head GI Surgery, IRCCS San Raffaele) — Principal investigator
First posted
Aug 5, 2022
Start date
Feb 16, 2022
Primary completion
May 19, 2026
Completion
May 19, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion